Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies

Antiviral Research

Volumn 133, Issue , 2016, Pages 218-222

  Cross, Robert W ^a,b   Mire, Chad E ^a,b   Branco, Luis M ^c   Geisbert, Joan B ^a,b   Rowland, Megan M ^c   Heinrich, Megan L ^c   Goba, Augustine ^d,e   Momoh, Mambu ^d,e,f   Grant, Donald S ^d,e   Fullah, Mohamed ^d,e   Khan, Sheik Humarr ^d,e   Robinson, James E ^g   Geisbert, Thomas W ^a,b   Garry, Robert F ^c,g  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c Zalgen Labs   (United States)

^d Kenema Government Hospital   (Sierra Leone)

^e MINISTRY OF HEALTH AND SANITATION   (Sierra Leone)

^f Polytechnic College   (Sierra Leone)

^g TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G1; NEUTRALIZING ANTIBODY; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURFACE; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; GUINEA PIG MODEL; IN VITRO STUDY; IN VIVO STUDY; LASSA FEVER; NONHUMAN; PARESIS; PRIORITY JOURNAL; SURVIVAL RATE; THERAPY EFFECT; TRANSIENT EXPRESSION; VIREMIA; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GUINEA PIG; HUMAN; IC50; IMMUNOLOGY; LASSA VIRUS; SERODIAGNOSIS; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; HUMANS; INHIBITORY CONCENTRATION 50; LASSA FEVER; LASSA VIRUS; NEUTRALIZATION TESTS;

EID: 84983735536     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.08.012     Document Type: Article

References (16)

1. Amorosa, V., MacNeil, A., McConnell, R., Patel, A., Dillon, K.E., Hamilton, K., Erickson, B.R., Campbell, S., Knust, B., Cannon, D., Miller, D., Manning, C., Rollin, P.E., Nichol, S.T., Imported Lassa fever, Pennsylvania, USA, 2010. Emerg. Infect. Dis. 16 (2010), 1598–1600.
2. Bausch, D.G., Hadi, C.M., Khan, S.H., Lertora, J.J., Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin. Infect. Dis. 51 (2010), 1435–1441.
3. Cummins, D., Bennett, D., Machin, S.J., Exchange transfusion of a patient with fulminant Lassa fever. Postgrad. Med. J. 67 (1991), 193–194.
4. Fichet-Calvet, E., Rogers, D.J., Risk maps of Lassa fever in west Africa. PLoS Negl. Trop. Dis., 3, 2009, e388.
5. Haas, W.H., Breuer, T., Pfaff, G., Schmitz, H., Kohler, P., Asper, M., Emmerich, P., Drosten, C., Golnitz, U., Fleischer, K., Gunther, S., Imported Lassa fever in Germany: surveillance and management of contact persons. Clin. Infect. Dis. 36 (2003), 1254–1258.
6. Hirabayashi, Y., Oka, S., Goto, H., Shimada, K., Kurata, T., Fisher-Hoch, S.P., McCormick, J.B., The first imported case of Lassa fever in Japan. Nihon Rinsho 47 (1989), 71–75.
7. Ibekwe, T., Lassa fever: the challenges of curtailing a deadly disease. Pan Afr. Med. J., 11, 2012, 55.
8. Jahrling, P.B., Frame, J.D., Rhoderick, J.B., Monson, M.H., Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans. R. Soc. Trop. Med. Hyg. 79 (1985), 380–384.
9. Leifer, E., Gocke, D.J., Bourne, H., Lassa fever, a new virus disease of man from west Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease. Am. J. Trop. Med. Hyg. 19 (1970), 677–679.
10. McCarthy, M., US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ, 349, 2014, g5488.
11. Mejias, A., Ramilo, O., Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants. Biologics 2 (2008), 433–439.
12. Robinson, J.E., Hastie, K.M., Cross, R.W., Yenni, R.E., Elliott, D.H., Rouelle, J.A., Kannadka, C.B., Smira, A.A., Garry, C.E., Bradley, B.T., Yu, H., Shaffer, J.G., Boisen, M.L., Hartnett, J.N., Zandonatti, M.A., Rowland, M.M., Heinrich, M.L., Martinez-Sobrido, L., Cheng, B., de la Torre, J.C., Andersen, K.G., Goba, A., Momoh, M., Fullah, M., Gbakie, M., Kanneh, L., Koroma, V.J., Fonnie, R., Jalloh, S.C., Kargbo, B., Vandi, M.A., Gbetuwa, M., Ikponmwosa, O., Asogun, D.A., Okokhere, P.O., Follarin, O.A., Schieffelin, J.S., Pitts, K.R., Geisbert, J.B., Kulakoski, P.C., Wilson, R.B., Happi, C.T., Sabeti, P.C., Gevao, S.M., Khan, S.H., Grant, D.S., Geisbert, T.W., Saphire, E.O., Branco, L.M., Garry, R.F., Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat. Commun., 7, 2016, 11544.
13. Safronetz, D., Rosenke, K., Westover, J.B., Martellaro, C., Okumura, A., Furuta, Y., Geisbert, J., Saturday, G., Komeno, T., Geisbert, T.W., Feldmann, H., Gowen, B.B., The broad-spectrum antiviral favipiravir protects Guinea pigs from lethal Lassa virus infection post-disease onset. Sci. Rep., 5, 2015, 14775.
14. Shaffer, J.G., Grant, D.S., Schieffelin, J.S., Boisen, M.L., Goba, A., Hartnett, J.N., Levy, D.C., Yenni, R.E., Moses, L.M., Fullah, M., Momoh, M., Fonnie, M., Fonnie, R., Kanneh, L., Koroma, V.J., Kargbo, K., Ottomassathien, D., Muncy, I.J., Jones, A.B., Illick, M.M., Kulakosky, P.C., Haislip, A.M., Bishop, C.M., Elliot, D.H., Brown, B.L., Zhu, H., Hastie, K.M., Andersen, K.G., Gire, S.K., Tabrizi, S., Tariyal, R., Stremlau, M., Matschiner, A., Sampey, D.B., Spence, J.S., Cross, R.W., Geisbert, J.B., Folarin, O.A., Happi, C.T., Pitts, K.R., Geske, F.J., Geisbert, T.W., Saphire, E.O., Robinson, J.E., Wilson, R.B., Sabeti, P.C., Henderson, L.A., Khan, S.H., Bausch, D.G., Branco, L.M., Garry, R.F., Viral Hemorrhagic Fever, C. Lassa fever in post-conflict Sierra Leone. PLoS Negl. Trop. Dis., 8, 2014, e2748.
15. Stephenson, E.H., Larson, E.W., Dominik, J.W., Effect of environmental factors on aerosol-induced Lassa virus infection. J. Med. Virol. 14 (1984), 295–303.
16. WHO, WHO Publishes List of Top Emerging Diseases Likely to Cause Major Epidemics. 2016, World Health Organization (accessed 31.05.16.) http://www.who.int/medicines/ebola-treatment/WHO-list-of-top-emerging-diseases/en/.